SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Quint JK, Wedzicha JA. The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2007; 119: 106571.
  • 2
    Tirouvanziam R. Neutrophilic inflammation as a major determinant in the progression of cystic fibrosis. Drug News Perspect 2006; 19: 60914.
  • 3
    Wang Q, Doerschuk CM, Mizgerd JP. Neutrophils in innate immunity. Semin Respir Crit Care Med 2004; 25: 3341.
  • 4
    Tsai HH, Frost E, To V, Robinson S, ffrench-Constant C, Geertman R, Ransohoff RM, Miller RH. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 2002; 110: 37383.
  • 5
    Stillie R, Farooq SM, Gordon JR, Stadnyk AW. The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol 2009; 86: 52943.
  • 6
    Ajuebor MN, Zagorski J, Kunkel SL, Strieter RM, Hogaboam CM. Contrasting roles for CXCR2 during experimental colitis. Exp Mol Path 2004; 76: 18.
  • 7
    Mackerness KJ, Jenkins GR, Bush A, Jose PJ. Characterisation of the range of neutrophil stimulating mediators in cystic fibrosis sputum. Thorax 2008; 63: 61420.
  • 8
    Mukaida N, Harada A, Matsushima K. A novel leukocyte chemotactic and activating cytokine, interleukin-8 (IL-8). Canc Res 1995; 80: 26186.
  • 9
    Weathington NM, van Houwelingen AH, Noerager BD, Jackson PL, Kraneveld AD, Galin FS, Folkerts G, Nijkamp FP, Blalock JE. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 2006; 12: 31723.
  • 10
    Zhang Z, Cherryholmes G, Chang F, Rose DM, Schraufstatter I, Shively JE. Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. Eur J Immonol 2009; 39: 318194.
  • 11
    Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009; 121: 5568.
  • 12
    Sarau HM, Widdowson KL, Palovich MR, White JR, Underwood DC, Griswold DE. Interleukin-8 receptor (CXCR2) antagonists. In: New Drugs for Asthma, Allergy and COPD: Progress in Respiratory Research, 31 edn, eds Hansel TT, Barnes PJ. Basel: Kargel, 2001; 2936.
  • 13
    Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, Tsai M, Sadeh J, Magnussen H. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Resp J 2010; 35: 56470.
  • 14
    Dwyer MP, Yu Y, Chao J, Aki C, Chao J, Biju P, Girijavallabhan V, Rindgen D, Bond R, Mayer-Ezel R, Jakway J, Hipkin RW, Fossetta J, Gonsiorek W, Bian H, Fan X, Terminelli C, Fine J, Lundell D, Merritt JR, Rokosz LL, Kaiser B, Li G, Wang W, Stauffer T, Ozgur L, Baldwin J, Taveras AG. Discovery of 2-Hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. J Med Chem 2006; 49: 76036.
  • 15
    Busch-Petersen J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr Top Med Chem 2006; 6: 134552.
  • 16
    Carpenter DC, Rumsey WL, Busch-Petersen J, Sarau HM, Salmon M. The selective CXCR2 receptor antagonist SB-656933 inhibits CXCL1-induced neutrophil CD11b expression in human whole blood. Eur Resp J 2004; 24: 218s.
  • 17
    Salmon M, Carpenter DC, Dehaas C, Tal-Singer R, Sarau HM, Underwood DC. Inhibition of LPS-induced neutrophil recruitment in the lungs correlates with modulation of neutrophil CD11b expression using the selective CXCR2 receptor antagonist SB-656933. Eur Resp J 2004; 24: 218s.
  • 18
    Nicholson GC, Tennant RC, Carpenter DC, Sarau HM, Kon OM, Barnes PJ, Salmon M, Vessey RS, Tal-Singer R, Hansel TT. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulm Pharm Ther 2007; 20: 529.
  • 19
    Holz O, Jorres RA, Timm P, Mucke M, Richter K, Koschyk S, Magnussen H. Ozone-induced airway inflammatory changes differ between individuals and are reproducible. Am J Respir Crit Care Med 1999; 159: 77684.
  • 20
    McDonnell WF, Horstman DH, Abdul-Salaam S, Raggio LJ, Green JA. The respiratory responses of subjects with allergic rhinitis to ozone exposure and their relationship to nonspecific airway reactivity. Toxicol Ind Health 1987; 4: 50717.
  • 21
    Nightingale JA, Rogers DF, Barnes PJ. Effect of inhaled ozone on exhaled nitric oxide, pulmonary function, and induced sputum in normal and asthmatic subjects. Thorax 1999; 54: 10619.
  • 22
    Vagaggini B, Carnevali S, Macchioni P, Taccola M, Fornai E, Bacci E, Bartoli ML, Cianchetti S, Dente FL, Di Franco A, Giannini D, Paggiaro PL. Airway inflammatory response to ozone in subjects with different asthma severity. Eur Resp J 1999; 13: 27480.
  • 23
    Vagaggini B, Taccola M, Conti I, Carnevali S, Cianchetti S, Bartoli ML, Bacci E, Dente FL, Di Franco A, Giannini D, Paggiaro PL. Budesonide reduces neutrophilic but not functional airway response to ozone in mild asthmatics. Am J Respir Crit Care Med 2001; 164: 21726.
  • 24
    Schelegle ES, Siefkin AD, McDonald RJ. Time course of ozone-induced neutrophilia in normal humans. Am Rev Resp Dis 1991; 143: 1353135.
  • 25
    Alexis NE, Lay JC, Haczku A, Gong H, Linn W, Hazucha MJ, Harris B, Tal-Singer R, Peden DB. Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers. Environ Health Perspect 2008; 116: 799805.
  • 26
    Holz O, Tal-Singer R, Kanniess F, Simpson KJ, Gibson A, Vessey RSJ, Janicki S, Magnussen H, Jörres RA, Richter K. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharm 2005; 45: 498503.
  • 27
    Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Ann Rev Immunol 2003; 15: 675705.
  • 28
    Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S, Bauman JG, Islam I, Ghannam A, Buckman B, Shaw K, Wei GP, Xu W, Zhao Z, Ho E, Shen J, Oanh H, Subramanyam B, Vergona R, Taub D, Dunning L, Harvey S, Snider RM, Hesselgesser J, Morrissey MM, Perez HD, Horuk R. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000; 275: 190008.
  • 29
    Liston TE, Conklyn MJ, Houser J, Wilner KD, Johnson A, Apseloff G, Whitacre C, Showell HJ. Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration. Br J Clin Pharmacol 1998; 45: 11521.
  • 30
    Khalilieh S, Tsai M, de Vries D, Kraan M. Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy volunteers. Eur Resp J 2007; 30: 613S.
  • 31
    Hartl D, Latzin P, Hordijk P, Marcos V, Rudolph C, Woischnik M, Krauss-Etschmann S, Koller B, Reinhardt D, Roscher AA, Roos D, Griese M. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007; 13: 142330.
  • 32
    Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN, Shapiro SD. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med 1998; 4: 6158.
  • 33
    Tkalcevic J, Novelli M, Phylactides M, Iredale JP, Segal AW, Roes J. Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity 2000; 12: 20110.
  • 34
    Kirkham PA, Spooner G, Rahman I, Rossi AG. Macrophage phagocytosis of apoptotic neutrophils is compromised by matrix proteins modified by cigarette smoke and lipid peroxidation products. Biochem Biophys Res Comm 2004; 318: 327.
  • 35
    Marcos V, Zhou Z, Yildirim AO, Bohla A, Hector A, Vitkov L, Wiedenbauer EM, Krautgartner WD, Stoiber W, Belohradsky BH, Rieber N, Kormann M, Koller B, Roscher A, Roos D, Griese M, Eickelberg O, Doring G, Mall MA, Hartl D. CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation. Nat Med 2010; 16: 101823.
  • 36
    Konstan MW, Doring G, Lands LC, Hilliard KA, Koker P, Bhattacharya S, Staab A, Hamilton AL. Results of a Phase II clinical trial BIIL 248 BS (an LTB4 receptor antagonist)for the treatment of CF lung disease. Ped Pulm 2005; 40: 1256.
  • 37
    Gaga M, Nair PK, Hargreave F, Sadeh J, Chanez P. SCH527123, a novel treatment option for severe neutrophilic asthma. Am J Respir Crit Care Med 2010; 181: A6762.
  • 38
    Magnussen H, Holz O, Watz H, Sauer M, Khanskaya I, Gann L, Stryszak P, Staudinger H, Sadeh J. Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD. Eur Resp J 2010; 36: 38s.